Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 11/20 | 0.66 |
| ▸ | MEN1 | O00255 | 9/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.66 |
| ▸ | GAA | P10253 | 3/20 | 0.66 |
| ▸ | MAPT | P10636 | 8/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | USP2 | O75604 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15836647 | 0.86 | KMT2A (0.70) | KMT2AMEN1ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL17066624 | 0.83 | KMT2A (0.59) | KMT2AMEN1ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL13454767 | 0.82 | KMT2A (0.67) | KMT2AMEN1ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL17066596 | 0.81 | MAPT (0.64) | KMT2AMEN1ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL17066565 | 0.81 | KMT2A (0.57) | KMT2AMEN1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL13453770 | 0.80 | ALDH1A1 (0.69) | KMT2AMEN1ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL13453805 | 0.80 | KMT2A (0.66) | KMT2AMEN1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL13470458 | 0.80 | ALDH1A1 (0.62) | KMT2AMEN1ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL13454397 | 0.80 | KMT2A (0.55) | KMT2AMEN1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL17066505 | 0.80 | MAPT (0.69) | KMT2AMEN1ALDH1A1SMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | KMT2A 3667/4885MEN1 3121/4885ALDH1A1 4348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.